EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 39 / No 11 (Novembre 2023) Med Sci (Paris), 39 11 (2023) 889-892 References
Issue
Med Sci (Paris)
Volume 39, Number 11, Novembre 2023
Nos jeunes pousses ont du talent !
Page(s) 889 - 892
Section Partenariat médecine/sciences - Écoles doctorales - Masters
DOI https://doi.org/10.1051/medsci/2023126
Published online 29 November 2023
  1. The International Agency for Research on Cancer (IARC). Global Cancer Observatory, 2020. [Google Scholar]
  2. Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin 2018 ; 68 : 7–30. [CrossRef] [PubMed] [Google Scholar]
  3. The Cancer Genome Atlas Network. Genomic Classification of Cutaneous Melanoma. Cell 2015 ; 161 : 1681–1696. [CrossRef] [PubMed] [Google Scholar]
  4. Samatar AA, Poulikakos PI. Targeting RAS-ERK signalling in cancer: promises and challenges. Nat Rev Drug Discov 2014 ; 13 : 928–942. [CrossRef] [PubMed] [Google Scholar]
  5. Yu C, Liu X, Yang J et al. Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma. Front Immunol 2019 ; 10 : 990. [CrossRef] [PubMed] [Google Scholar]
  6. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012 ; 367 : 1694–1703. [CrossRef] [PubMed] [Google Scholar]
  7. Long GV, Weber JS, Infante JR, et al. Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib. J Clin Oncol 2016 ; 34 : 871–878. [CrossRef] [PubMed] [Google Scholar]
  8. Luke JJ, Flaherty KT, Ribas A, Long GV. Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol 2017 ; 14 : 463–482. [PubMed] [Google Scholar]
  9. Kalaora S, Nagler A, Wargo JA, Samuels Y. Mechanisms of immune activation and regulation: lessons from melanoma. Nat Rev Cancer 2022; 22 : 195–207. [CrossRef] [PubMed] [Google Scholar]
  10. Sumimoto H, Imabayashi F, Iwata T, Kawakami Y. The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J Exp Med 2006, 203 ; 7 : 1651–1656. [CrossRef] [PubMed] [Google Scholar]
  11. Frederick DT, Piris A, Cogdill AP, et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res 2013 ; 19 : 1225–1231. [CrossRef] [PubMed] [Google Scholar]
  12. Reddy SM, Reuben A, Wargo JA. Influences of BRAF Inhibitors on the Immune Microenvironment and the Rationale for Combined Molecular and Immune Targeted Therapy. Curr Oncol Rep 2016 ; 18 : 42. [CrossRef] [PubMed] [Google Scholar]
  13. Ribas A, Butler M, Lutzky J, et al. Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma. JCO 2015 ; 15 : 3003. [CrossRef] [Google Scholar]
  14. Haas L, Elewaut A, Gerard CL, et al. Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma. Nat Cancer 2021; 2 : 7. [Google Scholar]
  15. Long GV, Carlino MS, Au-Yeung G, et al. NeoTrio: Randomized trial of neoadjuvant (NAT) pembrolizumab (Pembro) alone, in sequence (SEQ) with, or concurrent (CON) with dabrafenib plus trametinib (D+T) in resectable BRAF-mutant stage III melanoma to determine optimal combination of therapy. JCO 2022; 40 : 9503. [CrossRef] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.